Study of assessment for vascular endothelial function and renal function with irbesartan or amlodipine in hypertensive patients with proteinuria - prospective randomized controlled trial
- Conditions
- Hypertension with proteinuria
- Registration Number
- JPRN-UMIN000004569
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1) history of anaphylaxis of irbesartan or amlodipine, 2) patients who did not receive an antihypertensive treatment with angiotensin II receptor blockers (ARB), angiotensin converting enzyme (ACE) inhibitors or rennin inhibitor before the enrollment, 3) secondary hypertension, 4) history of stroke, myocardial infarction or cardiovascular disease, 5) nephrosis, 6) genetic renal disease, 7) patients with nephritis treated by corticosteroids, 8) hepatic dysfunction, 9) moderate heart failure (New York heart Association classes II or more), 10) patients with cancer or severe disease, 11) uncontrolled diabetic mellitus (HbA1c 8.0% or more), 12) bronchial asthma, 13) pregnancy, 14) patients who are inadequate to enter this study due to the other reasons by physician's judgments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in coronary vascular resistance measured by a PET (positron-emission tomography)
- Secondary Outcome Measures
Name Time Method 1) inulin clearance, 2) ambulatory blood pressure and heart rate, 3) blood test, urinary test and biomarker, 4) change in Flow mediated dilatation (FMD), 5) safety parameter